Oral contraceptive pills market to reach $22.9 billion by 2023 - Study

8 January 2016
research-labbig

The global oral contraceptive pills market is expected to reach an estimated value of $22.9 billion in 2023 at the annual growth rate of 6.6% against $13.1 billion in 2014, according to a report by Transparency Market Research.

Oral contraceptive pills are the most common form of reversible contraception in the developed economies of the world such as the USA, Canada, the Western Europe and Australia. Their high effectiveness (99.9% when accurately used and 92% when typically used) and convenience in use, drive the oral contraceptive pills segment.

Based on the product types, the global oral contraceptives market is segmented into combination pills, progestin only pills and others. Combination pills are further categorized into three segments including monophasic pills, triphasic pills and others.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical